2018會計年度： 百靈佳殷格翰持續成長、增加投資

德國殷格翰，2019年4月17日 -以研發為導向的製藥公司百靈佳殷格翰於2018年的年度淨銷售額為175億歐元。經過匯率調整、並納入與賽諾菲在2017年資產交換所帶來的一次性影響後，淨銷售額成長了4%。研發投資金額也增至32億歐元（+2.8%），佔年度淨銷售額18.1%。

百靈佳殷格翰聚焦特定的治療領域。執行董事會主席Hubertus von Baumbach表示：「我們希望為優質的癌症治療作出更多貢獻。此外，我們在纖維化、新陳代謝和免疫疾病方面的研究也不遺餘力。我們的研發產品線可以說非常豐富。」

有形資產投資將近10億歐元（+9%），更勝以往。營業收益持平為35億歐元（-0.4%），而集團稅後利潤增至21億歐元。負責財務的執行董事會成員Michael Schmelmer指出：「2018年，淨銷售額的報酬率從19.3%增至19.8%，而股東權益比率也從近38%上升至40%。因此從財務角度來看，我們是一家非常健全的公司。」

所有地區的平均員工數略有增加，來到50,370人（+2%）。 

 

人類用藥- 強大的產品組合

人類處方藥物的銷售額為126億歐元，佔2018年淨銷售額的72%。即使面臨創新藥物的專利到期，可預見淨銷售額下滑，但此事業領域的亮眼表現足以相抵，實現5.1%的成長（經匯率調整）。全球授權業務的收入低於前一年，使此事業領域的整體成長率降至3.3%。

一如往年，呼吸道藥物適喘樂SPIRIVA^®有最高的淨銷售額，高達24億歐元（經匯率調整-11.4%），其次為第2型糖尿病藥物恩排糖 JARDIANCE^®，包括恩美糖 JARDIANCE DUO^®和糖順平 GLYXAMBI^®，達18億歐元（經匯率調整+52.5%）；接著則是抗凝血劑普栓達 PRADAXA^®，達15億歐元（經匯率調整+7.0%）、第2型糖尿病藥物糖漸平 TRAJENTA^®，達14億歐元（經匯率調整+9.0%） ，以及用於治療原發性肺纖維化（IPF）的抑肺纖 OFEV^®，達11億歐元（經匯率調整+28.7%）。

人類藥物的研發投資為28億歐元，相當於人類藥物淨銷售額的22.1%。處於不同研發進程的90個研究案中，目標有75%能夠成為全新有效成分、或是新治療領域的全新類別。在腫瘤方面，專注於肺癌、胃癌和腸癌；在纖維化疾病方面，則專注系統性硬化症相關間質性肺疾病。在新陳代謝疾病方面，非酒精性脂肪性肝炎是研究焦點。在免疫疾病方面，研究聚焦皮膚和腸道的慢性發炎疾病。其他研究案則包括中樞神經系統疾病，如阿滋海默症和精神分裂症，以及肥胖症和視網膜病變。 

 

動物保健 - 技術整合完成

在動物保健方面，我們的重點在於推出創新疫苗、抗寄生蟲藥物、以及針對牲畜和寵物的更多治療方案。2018年，三種抗寄生蟲藥物全能狗 NEXGARD^®、蚤不到 FRONTLINE^®、犬新寶 HEARTGARD^®以及豬疫苗 INGELVAC CIRCOFLEX^®是四個最暢銷的產品。淨銷售額達40億歐元，占總淨銷售額的23%。

在賽諾菲的動物保健事業單位梅里亞（Merial，台灣註冊為龍馬躍）交易的第二年，動物保健事業有顯著的淨銷售成長，經匯率調整後為5.6%，而整合工作也同步進行。Hubertus von Baumbach表示：「我們自始致力持續為客戶提供優質產品。這方面我們有長足成長，技術整合也順利完成。與人類藥物研究相關的動物保健，其創新潛力特別值得關注。」

 

生物製劑合約製造業務保持領先地位

生物製劑合約製造業務在2018會計年度保持領先地位，佔總淨銷售額的4%。訂單持續成長，為生物製劑生產帶來高度產能利用。

 

展望2019年

百靈佳殷格翰預計本會計年度的淨銷售額將微幅成長，也會有相對密集的投資活動。Hubertus von Baumbach指出：「光是在歐洲，我們就計劃在未來五年內投資超過30億歐元，關鍵前提是我們必須維持在歐洲的整體競爭力。」

 

關於百靈佳殷格翰

身為以研發為導向的製藥公司，百靈佳殷格翰旨在促進患者的健康與生活品質，在需要更好治療方法的疾病領域上持續專注，以求可有拓展和延長病患生命的創新。同時，更也在動物健康的預防與治療上積極倡議和推動。

自1885年成立以來，百靈佳殷格翰一直維持家族企業的高獨立性，而成為全球20大領先的製藥企業之一。全球五萬名同仁在人類處方用藥、動物用藥與生物製劑製造三大事業領域上，持續透過創新而展現價值。在2018年，百靈佳殷格翰總體營業淨銷售額將近175億歐元，其中，研發投資金額超過32億歐元，相當於淨銷售額的18.1%。

台灣百靈佳殷格翰股份有限公司是百靈佳殷格翰在台子公司，成立於1975年，迄今已逾43年，目前在台灣北中南共設有3個辦公室，員工近300人。人類處方用藥及動物用藥是公司的核心業務，持續在呼吸道疾病、癌症、糖尿病、心血管疾病、帕金森氏症、纖維化疾病、HIV等領域幫助更多病患；在動物保健方面，我們持續在內外寄生蟲預防與心臟疾病治療上協助伴侶動物與其照顧者，更也在許多疾病上協助經濟動物產業的畜場主人，如豬隻環狀病毒及藍耳病、家禽馬立克病及新城雞病…等。

近年，台灣百靈佳殷格翰在藥業的創新極受認可，除了持續的快速成長，更也是台灣目前唯一在2016至2019連續四年獲得傑出雇主認證的企業。

身為家族藥企，百靈佳殷格翰專注於未來世代的長遠成功，而非短期利潤。因此，我們透過自身的資源、開放性的合作夥伴關係和研發上的策略聯盟來逐步有機成長，更責無旁貸地承擔對人類和環境的社會責任。

想了解更多關於百靈佳殷格翰公司的資訊，請上www.boehringer-ingelheim.com或參閱我們的年度報告：http://annualreport.boehringer-ingelheim.com。

 

 

Ingelheim, Germany, 17 April 2019 - The research-driven pharmaceutical company Boehringer Ingelheim ended 2018 with net sales of 17.5 billion euros. Adjusted for currency effects, as well as one-off effects due to the asset swap with Sanofi in 2017, net sales grew by 4 per cent. At 3.2 billion euros (+2.8%), R&D expenses increased to 18.1 per cent of annual net sales.

In the process, the company has focused on specific therapeutic areas. “We want to make a significant contribution towards a superior treatment of cancer,” says Hubertus von Baumbach, Chairman of the Board of Managing Directors. “In addition, we are conducting research, among others, into fibrotic, metabolic and immunological diseases. Our research pipeline is well-filled.”

At almost 1 billion euros (+9%), investments in tangible assets were higher than ever before. Operating income again amounted to 3.5 billion euros (- 0.4%), while Group profit after tax increased to 2.1 billion euros. “In 2018, the return on net sales increased from 19.3 to 19.8 per cent, while our equity ratio rose from nearly 38 per cent to 40 per cent. Thus we are also a very healthy company from a financial point of view,” remarks Michael Schmelmer, Member of the Board of Managing Directors responsible for Finance.

The average number of employees in all regions increased slightly to a total of 50,370 (+2%).

 

Human pharmaceuticals – strong portfolio

At 12.6 billion euros, human pharmaceuticals contributed to 72 per cent of total net sales in 2018. Foreseeable declines in net sales, due to expiring patents for innovative medicines, were more than compensated for, this business thereby achieving currency-adjusted growth of 5.1 per cent. Revenues from the global licensing business were lower than in the previous year and have reduced the overall rate of growth in this business area to 3.3 per cent.

As in previous years, the respiratory medicine SPIRIVA^® achieved the highest net sales contributions with 2.4 billion euros (-11.4% currency-adjusted), followed by the type-2 diabetes medicine family JARDIANCE^®, including JARDIANCE DUO^® and GLYXAMBI^®, with 1.8 billion euros (+52.5% currency-adjusted), the anticoagulant PRADAXA^® with 1.5 billion euros (+7.0% currency-adjusted), the type-2 diabetes medicine TRAJENTA^® with 1.4 billion euros (+9.0% currency-adjusted), as well as OFEV^® for the treatment of idiopathic pulmonary fibrosis (IPF), with 1.1 billion euros (+28.7% currency-adjusted).

At 2.8 billion euros, research and development investments in human pharmaceuticals corresponded to a 22.1% share of human pharmaceuticals’ net sales. For the total of 90 projects in all phases of the research process, the goal is for 75 per cent of them to be either the first molecules in their active ingredient class or the first in a new therapeutic area. In oncology, the focal points are cancers of the lung, stomach and intestine, while in fibrotic diseases the focus is on systemic scleroderma with interstitial lung disease. In metabolic diseases, non-alcoholic steatohepatitis is the main focus of research. In immunology, research is giving attention to chronic inflammatory diseases of the skin and intestine. Other projects address diseases of the central nervous system, such as Alzheimer’s and schizophrenia, obesity and retinopathy.

 

Animal health – Technical integration completed

In animal health, our focus is on innovative vaccines, antiparasitic medicines and further therapy solutions for livestock and pets. In 2018, the three antiparasitic medicines NEXGARD^®, FRONTLINE^® and HEARTGARD^®, plus the vaccine INGELVAC CIRCOFLEX^®, were the four best-selling products. Net sales of 4 billion euros represented 23 per cent of total net sales.

In the second year of the Merial transaction, this business has thereby achieved significant net sales growth, with a currency-adjusted rate of 5.6 per cent, while simultaneously undertaking integration efforts. “We have focused on providing our customers with continuous supply from day one. As a result, we have achieved good growth and the technical integration is successfully completed,” says Hubertus von Baumbach. The innovation potential in animal health, where it interrelates with human pharmaceutical research, deserves particular attention.

 

Biopharmaceutical contract manufacturing maintains lead position

The biopharmaceuticals business maintained its lead position in the contract manufacturing segment in the financial year 2018 and provided 4 per cent of overall net sales. The order situation has continued to develop positively and provided for a high level of capacity utilization in biopharmaceutical production.

 

Outlook for 2019

For the current financial year, Boehringer Ingelheim is expecting slight growth in net sales and further intensive investment activities on a comparable basis. “In Europe alone we are planning investments of more than 3 billion euros within the next five years,” says von Baumbach. “The key precondition for this are competitive overall conditions at our European sites.”

 

Boehringer Ingelheim

Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost
3.2 billion euros corresponded to 18.1 per cent of net sales.

Boehringer Ingelheim, Taiwan has served in Taiwan since 1975 as a healthy issue solution provider with nearly 300 employees and 3 different offices located in north, central and south Taiwan. With core business in Human Pharm and Animal Health, we support patients in the area of the respiratory, oncology, diabetes, cardiovascular, Parkinson's disease, fibrosis disease, HIV and more. We support companion animals and their owners in parasite prevention and the treatment for heart disease, also support Livestock farmer in serval disease prevention, such as porcine reproductive and respiratory syndrome, Newcastle Disease and more.

Boehringer Ingelheim, Taiwan has become the fastest growing and most innovative company within the industry in recent years. Also, Boehringer Ingelheim is the only company received Top Employer Recognition for 4 years in a row from 2016 to 2019

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards humankind and the environment.

 

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.